Logo 1 Logo 2

Clinical Trial Details

Trial ID: L3976
Source ID: NCT01353469
Associated Drug: Insulin Human/Insuman Comb 25 (Hr1799)
Title: Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy
Acronym: Insuman-C25-CN
Status: COMPLETED
Study Results: NO
Results:
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG: Insulin human/Insuman Comb 25 (HR1799)|DRUG: Insulin human/Novolin® 30R
Outcome Measures: Primary: Change in HbA1c from baseline to the end of treatment, 24 weeks | Secondary: Change in fasting plasma glucose from baseline to the end of treatment, 24 weeks
Sponsor/Collaborators: Sponsor: Sanofi
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE3
Enrollment: 485
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2011-05
Completion Date: 2012-11
Results First Posted:
Last Update Posted: 2013-02-27
Locations: Investigational Site Number 156024, Beijing, 100088, China|Investigational Site Number 156010, Beijing, 100730, China|Investigational Site Number 156001, Beijing, 100853, China|Investigational Site Number 156033, Changchun, 130011, China|Investigational Site Number 156017, Changchun, 130041, China|Investigational Site Number 156005, Changsha, 410008, China|Investigational Site Number 156021, Chengdu, 610072, China|Investigational Site Number 156006, Chongqing, 400016, China|Investigational Site Number 156032, Hangzhou, 310013, China|Investigational Site Number 156007, Harbin, 150001, China|Investigational Site Number 156020, Hefei, 230001, China|Investigational Site Number 156016, Nanjing, 210006, China|Investigational Site Number 156018, Nanjing, 210011, China|Investigational Site Number 156002, Shanghai, 200003, China|Investigational Site Number 156023, Shanghai, 200040, China|Investigational Site Number 156031, Shanghai, 200062, China|Investigational Site Number 156004, Shanghai, 200065, China|Investigational Site Number 156027, Shenyang, 110022, China|Investigational Site Number 156029, Suzhou, 215004, China|Investigational Site Number 156025, Tianjin, 300052, China|Investigational Site Number 156003, Wuhan, 430022, China|Investigational Site Number 156008, Xi'An, 710032, China|Investigational Site Number 156009, Xi'An, 710061, China
URL: https://clinicaltrials.gov/show/NCT01353469

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress